OUTCOMES OF USING GENERIC LETERMOVIR FOR CMV PROPHYLAXIS IN HSCT: RETROSPECTIVE ANALYSIS (EBMT 2026) - Feb 7, 2026 - Abstract #P177; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "Antiviral prophylaxis with Ganciclovir or Valganciclovir is limited by myelosuppression. Cumulative incidence of CMV reactivation was marginally higher in our study compared to Western data. All patients responded well to first line Pre-emptive therapy. Time of onset of CMV reactivation was early."
Retrospective data • Beta-Thalassemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Sickle Cell Disease
|
|
Anil Aribandi1; Chaitanya G B1; Ranjit Kumar C.S1; Bhavya Sri Vallamshetla1
|